The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease

被引：18

作者：

Kalantarinia K. ^{[1
]}

Okusa M.D. ^{[1
]}

机构：

[1] Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22908

来源：

Current Diabetes Reports | 2006年 / 6卷 / 1期

关键词：

Diabetic Nephropathy; Captopril; Enalapril; Losartan; Angiotensin Converting Enzyme Inhibitor;

D O I：

10.1007/s11892-006-0045-4

中图分类号：

学科分类号：

摘要：

Diabetic nephropathy, the most common cause of end-stage renal disease in the United States, is also associated with increased cardiovascular mortality. The renin-angiotensin-aldosterone system (RAAS) plays a central role in the development and progression of kidney disease and cardiovascular disease. Randomized, controlled trials have demonstrated renoprotection with the use of angiotensin receptor blockers (ARBs) in type 2 and angiotensin-converting enzyme inhibitors (ACEIs) in type I diabetes. More recent studies have demonstrated similar cardiovascular benefits with the use of ARBs compared with ACEIs. The combination of the two classes of RAAS blockers has been investigated in large studies of patients with heart failure and after myocardial infarction, and a few small studies of patients with diabetic nephropathy. In this review, we summarized the results of the studies on the benefits of ARBs, ACEIs, and their combination in patients with diabetic nephropathy or cardiovascular diseases. Copyright © 2006 by Current Science Inc.

引用

页码：8 / 16

页数：8

共 65 条

[11]

Naftilan A.J., Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth, Curr Opin Nephrol Hypertens, 3, pp. 218-227, (1994)

[12]

Dzau V.J., Tissue renin-angiotensin system in myocardial hypertrophy and failure, Arch Intern Med, 153, pp. 937-942, (1993)

[13]

Leehey D.J., Singh A.K., Alavi N., Singh R., Role of angiotensin II in diabetic nephropathy, Kidney Int Suppl, 77, (2000)

[14]

Weiss D., Sorescu D., Taylor W.R., Angiotensin II and atherosclerosis, Am J Cardiol, 87, (2001)

[15]

Gainer J.V., Morrow J.D., Loveland A., Et al., Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects, N Engl J Med, 339, pp. 1285-1292, (1998)

[16]

Wei C.C., Tian B., Perry G., Et al., Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene, Am J Physiol Heart Circ Physiol, 282, (2002)

[17]

van den Meiracker A.H., Man in't Veld A.J., Admiraal P.J., Et al., Partial escape of angiotensin converting enzyme (ACE) Inhibition during prolonged ACE Inhibitor treatment: Does it exist and does it affect the antihypertensive response?, J Hypertens, 10, pp. 803-812, (1992)

[18]

Borghi C., Boschi S., Ambrosioni E., Et al., Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardlal infarction treated with ACE inhibitors, J Clin Pharmacol, 33, pp. 40-45, (1993)

[19]

Struthers A.D., Aldosterone escape during ACE inhibitor therapy in chronic heart failure, Eur Heart J, 16, SUPPL. N, pp. 103-106, (1995)

[20]

Roig E., Perez-Villa F., Morales M., Et al., Clinical implications of increased plasma anglotensin II despite ACE inhibitor therapy in patients with congestive heart failure, Eur Heart J, 21, pp. 53-57, (2000)

← 1 2 3 4 5 6 7 →